Tumor Profiler Study Confirms Value of Multiomics in Melanoma Care
A recent study published in Nature Medicine by the Tumor Profiler (TuPro) Consortium, with important contributions from the DQBM Bodenmiller Lab, provides strong evidence supporting multiomics tumor profiling as a clinically useful tool in melanoma care.
The consortium analyzed tumor samples from 116 melanoma patients using nine advanced single-cell and multiomics technologies. A multidisciplinary molecular tumor board leveraged these comprehensive data sets to deliver personalized treatment recommendations within a clinically relevant turnaround time of four weeks.
Patients treated with personalized therapies informed by multiomics data—particularly those receiving treatments beyond standard care—showed significant clinical benefits, achieving a response rate of 38% and a disease control rate of 54%. Progression-free survival was notably extended to approximately six months in patients who had previously undergone multiple therapies.
This study demonstrates the feasibility and effectiveness of multiomics-driven clinical decision-making, highlighting the increasing impact of precision medicine in improving patient outcomes.
Publication Link: https://doi.org/10.1038/s41591-025-03715-6
